Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab
Finally, could you briefly discuss some of the cost issues associated with adding biologics to CT? How does the cost of bevacizumab compare with that of cetuximab? Given the outcome of the CALGB/SWOG 80405 study, what do you think is a cost-effective approach to using these agents?
There was a cost-effective analysis looking at CALGB 80405 which did the comparison of chemotherapy with bevacizumab, as opposed to chemotherapy plus cetuximab. That result suggested that perhaps bevacizumab was more cost effective than cetuximab. At the moment I think we as practicing oncologists are not bound to make our treatment decisions exclusively on cost. What I'm pleased to say is that we can often make those decisions based on what is really the optimal care for that specific patient, recognizing that we have to be mindful of cost considerations and ultimately I suspect our treatment paradigms will start to take that into account.
Unresectable Colon Cancer: Case 2
52-year-old woman newly diagnosed with metastatic CRC and is genotyped as part of her initial work up.
Sotorasib/Panitumumab Combo Improves PFS in Refractory KRAS G12C+ mCRC
October 23rd 2023The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C mutations.
Read More
T-IELs Could Hold the Key for CRC Immunotherapy
October 10th 2023Researchers identified different functions of groups of intraepithelial T cells (T-IELs) throughout the gastrointestinal tract, which could help inform future immunological treatment for patients with colorectal cancer.
Read More
CAPOX Regimen Appears Noninferior to FOLFOX in CRC
October 8th 2023The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and Education Award presentation abstract in the August 2023 Journal of the National Comprehensive Cancer Network.
Read More
